Fate Therapeutics (FATE) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 10.8% versus a loss of 79.3%. Over five years, FATE leads with a -98.3% price change compared with -98.6% for OTLK. Fate Therapeutics is the larger company by market cap ($111.8 million vs $94.9 million), about 1.2 times the size.
Fate Therapeutics converts more of its revenue into profit, with a net margin of -2051.1% versus -4416.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | OTLK |
|---|---|---|
| Share price | $0.919 | $0.39 |
| Market cap | $111.82M | $94.94M |
| 1-day change | -9.01% | -2.74% |
| YTD return | -6.22% | -75.32% |
| 1-year return | -10.78% | -79.26% |
| 5-year return | -98.25% | -98.58% |
| EPS (TTM) | $-1.03 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.65M | $1.41M |
| Revenue growth (YoY) | -51.24% | — |
| Net income (latest FY) | $-136.31M | $-62.42M |
| Gross margin | — | 4.05% |
| Operating margin | -2222.45% | -4744.25% |
| Net margin | -2051.08% | -4416.22% |
| 52-week high | $3.23 | $2.54 |
| 52-week low | $0.90 | $0.161 |
| Distance from 52-week high | -71.55% | -84.63% |
| Analyst consensus | buy | none |
| Avg. price target upside | +522.42% | +1189.74% |
| Average volume | 1.53M | 4.60M |
| Shares outstanding | 121.67M | 243.45M |
| Employees | 161 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed OTLK by 68.5 percentage points over the past year.
- Fate Therapeutics is more profitable, keeping -2051.1 cents of every revenue dollar as net income versus -4416.2 cents for Outlook Therapeutics.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
FATE vs OTLK FAQ
Which is bigger, Fate Therapeutics or Outlook Therapeutics?
Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $94.94M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, FATE or OTLK?
FATE returned -10.78% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.